Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. Our initial efforts have focused on treatments for Sickle Cell Disease, a genetic disorder.
Emmaus's lead commercial product is Endari®, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.